Neurology
Duodopa is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1
References
- Duodopa (levodopa/carbidopa intestinal gel) Summary of Product Characteristics. Available at: www.medicines.org.uk.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-ABBV-200147. Date of preparation: August 2020